Open AccessODAC Recommends Approval of PathVysion Assay Indicator of Response to Herceptin Therapy for Metastatic Breast Cancer
Author(s) -
Margot J. Fromer
Publication year - 2002
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000315330.48063.0d
Subject(s) - trastuzumab , medicine , metastatic breast cancer , companion diagnostic , breast cancer , oncology , clinical trial , cancer , targeted therapy , gynecology